DUA
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Keywords | Cancer Immunotherapy, Regenerative Medicine, Gene/Cell Therapy |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at DUA
Christopher Adrian Johnston
Founder, CEO/CTO
DUA Email Formats
DUA uses 1 email format. The most common is {second initial} (e.g., o@dua.earth), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{second initial} | o@dua.earth | 100% |
About DUA
DUA is a biotech company founded in 2024, developing "Velocity Proteins" to enable immune cell therapy to cure solid cancers. These proteins rebuild the immune system's ability to navigate dense tumors, leading to 95x more immune cells entering tumors compared to current industry approaches. DUA has completed extensive preclinical trials at Johns Hopkins and is currently fundraising for seed capital to complete IND-enabling toxicology and safety pharmacology studies. Our target market is ovarian cancer, with plans to expand to other solid cancers. We intend to use a B2B2C model, selling directly to hospitals, clinics, and pharmacies. Our executive team includes Adrian Johnston (Founder/CEO/CTO), Jarrett East (CMO), Adwoa Bostick (CDO), and Laud Anderson (CFO). Our board includes Gail Wasserman and Jim Muir.
DUA revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
DUA has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
DUA has never raised funding before.
Canada
Italy
United Kingdom
Frequently asked questions
4.8
40,000 users
